by Stacey Hawkins | Jun 1, 2020 | Metabolic & Cardiovascular Disease
Bacon-wrapped meatloaf, chicken and waffles, cronuts! Mmm…but no wonder some of us are getting a little pudgy. According to the Center for Disease Control (Atlanta, GA), 40 percent of adults and nearly 20 percent of children and adolescents in the U.S. are obese.... 
by Stacey Hawkins | Feb 7, 2019 | Groundbreaking New Therapies in Development
Decoding The Gut-Brain Axis Earlier this week, a newly published study made headlines for showing a direct link between the gut microbiome and depression. For the past several years, scientists have suspected a link between bugs in the gut and neurological health.... 
by Stacey Hawkins | Dec 7, 2016 | Neuroscience
Microbiome & Disease The biotech world is abuzz with talk of the latest microbiome startup launch Axial Biotherapeutics (Boston, MA). What caught our eye here at the WEEKLY is the company’s focus on the gut microbiome — the entire collection of microbes living in... 
by Stacey Hawkins | Dec 1, 2016 | Immunology
Fibrotic Disease Innovations Fibrotic diseases — organ and tissue disorders that occur as a result of the buildup of excessive scar tissue — are sounding the alarm in the biotech sector. A silent epidemic creeping up on the Western world involves non-alcoholic... 
by Stacey Hawkins | May 26, 2015 | Metabolic & Cardiovascular Disease
The Race Against Nash A silent epidemic creeping upon the Western world pushed the headline grabbing acquisition of a Phase 1 non-alcoholic steatohepatitis (NASH) drug last week. Boehringer Ingelheim (Ingelheim, Germany) acquired Pharmaxis (Sydney, Autralia) due to...
